Abstract
The outbreak of new coronavirus disease-20119 or COVID-19 infection has become a global health emergency at the beginning of this year. Currently, no specific vaccines and therapeutic medications are available to treat this disease. Even though several vaccine candidates are under investigation, it will take some time to make them available for the mass population. Hyperinflammation due to excessive cytokine release in COVID-19 infected patients with other inflammatory diseases makes lethal effects, including multiorgan failure and even death. The increasing gain of insight about the pathophysiology of this novel coronavirus enables experts to consider some commonly available anti-inflammatory drugs as potential immunomodulatory candidates for the cytokine release syndrome (CRS) treatment in COVID-19 infection. This review was conducted to discuss all the possible signalling pathways involved in COVID-19 related hyperinflammation. It also emphasized on the efficacy of both synthetic and natural therapeutic drugs for immunomodulation in the COVID-19 related CRS treatment.
Highlights
Coronavirus disease-2019 (COVID-19) is a respiratory syndrome disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a new strain of the Coronaviridae family of viruses.[1]
According to the recent case studies, COVID-19 manifested by severe pneumonia with alveolar damage, which leads to severe acute respiratory distress syndrome (ARDS) and in worse cases even death.[4]
Evidence suggests that SARS-CoV-2 infected patients who are already suffering from immune-rheumatological and other inflammatory diseases like rheumatoid arthritis (RA) are more fragile to cytokine release syndrome (CRS)-induced ARDS.[8,9,10]
Summary
Md Mohosin Rana1* ID 1Biomedical Engineering Graduate Program, University of Calgary, Calgary, Canada. No specific vaccines and therapeutic medications are available to treat this disease. Hyperinflammation due to excessive cytokine release in COVID-19 infected patients with other inflammatory diseases makes lethal effects, including multiorgan failure and even death. The increasing gain of insight about the pathophysiology of this novel coronavirus enables experts to consider some commonly available anti-inflammatory drugs as potential immunomodulatory candidates for the cytokine release syndrome (CRS) treatment in COVID-19 infection. This review was conducted to discuss all the possible signalling pathways involved in COVID-19 related hyperinflammation. It emphasized on the efficacy of both synthetic and natural therapeutic drugs for immunomodulation in the COVID-19 related CRS treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
